India's largest pharmaceutical contract manufacturer (CDMO), making formulations for other drug companies plus its own generics.
India's largest pharmaceutical contract manufacturer (CDMO), making formulations for other drug companies plus its own generics.
Makes formulations, finished tablets, injections and softgels, to the specifications of other drug companies, which sell them under their own labels, so income is contract-manufacturing fees spread across many customers rather than one product. It listed on the stock market in 2024.
Moat: narrow (scale, regulatory licence, process know-how). Largest-scale, multi-approval manufacturing base in India's CDMO market, though the space has several capable rivals.
Headquarters: Haridwar, India · Founded: 2004 · Employees: 18,010
Size Akums Drugs and Pharmaceuticals (AKUMS.NS) is an India Health Care company (Biotechnology) with a market value of $1.21B, the 552nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹716.15 on 18 Nov 2026.
Performance Over six months the shares gained 37.8%, against -20.5% for the median peer and +3.8% for the India market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue grew 17.5% over the last twelve months (peer median -1.6%); the operating margin is 10.4% (peer median -71.3%).
Valuation It trades at 25.6× forward earnings against a peer median of 41.3× (cheapest of 7).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.5 points above its cost of capital (13.5% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹48.3B | ₹43.6B | ₹41.2B | ₹41.8B | ₹36.5B |
| Revenue growth | — | +6% | -1% | +14% | — |
| Gross profit | ₹11.0B | ₹6.85B | ₹5.91B | ₹6.27B | ₹4.57B |
| EBITDA | ₹6.68B | ₹5.26B | ₹4.63B | ₹4.85B | ₹3.09B |
| Net income | ₹3.64B | ₹2.55B | ₹3.38B | -₹40.4M | ₹949M |
| Free cash flow | n/a | ₹9.80B | ₹1.90B | ₹1.55B | -₹1.85B |
| Capital expenditure | n/a | ₹2.31B | ₹2.72B | ₹3.11B | ₹3.29B |
| Total debt | ₹1.17B | ₹1.57B | ₹882M | ₹5.65B | ₹6.19B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals AKUMS.NS | $1.21B | +38% | +18% | 10% | 25.6× | 15.3% |
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AKUMS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.9% | -12.5% | 3rd highest of 21 |
| 6-month return | +37.8% | -20.5% | 2nd highest of 19 |
| Distance from 52-week high | -14.6% | -48.0% | 2nd highest of 21 |
| Revenue growth (TTM) | +17.5% | -1.6% | 6th highest of 15 |
| Operating margin | 10.4% | -71.3% | highest of 15 |
| Forward P/E | 25.6× | 41.3× | cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | 15.3% | 10.5% | 2nd most demanding of 5 |
| Growth delivered (Del g) | +9.9% | -10.0% | highest of 5 |
| Hurdle (Req g minus delivered) | +5.5 pp | +28.6 pp | least demanding of 5 |
| ROIC minus cost of capital | +5.5 pp | -8.7 pp | highest of 10 |
| EV / EBITDA | 14.6× | n/a | — |
| Net debt / EBITDA | -2.3× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 25.6× | 15.3% | +9.9% |
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 44.0× | 6.6% | -7.0% |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 26.5× | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 38.6× | 33.2% | -13.1% |
| Kardigan KARD | United States | $1.15B | n/a | n/a | n/a | n/a | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.15B | -25% | n/a | n/a | n/a | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | n/a | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 134.6× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.36B | -23% | +36% | -4% | 60.5× | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | n/a | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | n/a | n/a | n/a |
| Daan Gene 002030.SZ | China | $1.05B | -17% | +1% | -81% | n/a | 4.8% | -32.3% |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 28.4× | 14.3% | -5.8% |